Researchers
We support innovative research that can benefit society. Let us help you turn your ideas into meaningful progress for patients.
Our business is breakthroughs
We take cutting-edge innovations from the lab bench to the bedside, translating them into effective tools, treatments and diagnostics for people with cancer.
14
marketed drugs
£600m+
revenue from royalties and IP
150+
active licences
79
start-ups
£3bn+
raised by our start-up portfolio
Targeted breast cancer pill capivasertib (Truqap) approved for use by NHS
News
Truqap was discovered by AstraZeneca subsequent to a collaboration with Astex Therapeutics (and its collaboration with the Institute of Cancer Research and Cancer Research Horizons).
Latest news
Drug discovery and development capabilities
Spotlight
We're committed to driving therapeutic innovation in oncology, with six drug discovery sites and one focus: accelerating the discovery and development of new therapeutics. Our expertise spans target identification, validation and clinical positioning, through Hit identification and lead optimisation to the selection of candidate drugs for regulatory development, for both small molecule and antibody modalities.
Through partnership with the Cancer Research UK Centre for Drug Development we can also offer access to the capabilities and infrastructure needed to demonstrate clinical potential.
